- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05235009
LEVANTIS-0087A: GAGomes for Multi-Cancer Early Detection in Asymptomatic Adults (LEV87A) (LEV87A)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Multi-cancer early detection (MCED) could prevent 26% of all cancer-related deaths - an effect larger than averting all deaths from breast cancer alone. However, a societal program to implement MCED requires a practical, noninvasive, and affordable diagnostic modality that is sensitive and specific to all forms of cancers. Liquid biopsies represent front-runner modalities to this end but virtually all of them rely on genomics biomarkers, typically circulating free DNA (cfDNA), which capture <20% of cancers in stage I. In addition, they miss certain cancer types that shed little cfDNA, like brain or genitourinary tumors. Pilot studies show that free glycosaminoglycan profiles in plasma and urine, or free GAGomes, were promising noninvasive biomarkers of cancer metabolism that detected over a third of stage I cancers across 14 types, including brain and genitourinary tumors.
LEVANTIS-0087A (LEV87A) is a retrospective in vitro diagnostics clinical validation population cohort-based case-control study to develop free GAGome-based tests for multi-cancer early detection in adults asymptomatic for cancer and with no recent history of cancer (Sub-Study 1) and to validate their diagnostic performance in the target population (Sub-Study 2).
LEV87A uses retrospectively collected biospecimens from one or more population-based biobanks representative of the target population.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Francesco Gatto, PhD
- Phone Number: +46 (0)8 520 27 885
- Email: info@elypta.com
Study Locations
-
-
-
Stockholm, Sweden
- Recruiting
- Elypta AB
-
Contact:
- Francesco Gatto
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Sub-Study 1
Inclusion Criteria
Case Arm:
- At the baseline visit, >18 years old, any gender
- At the baseline visit, available biospecimens for both EDTA-plasma and urine
- Diagnosis of cancer before or at the baseline visit or diagnosis of cancer after the baseline visit
- If a diagnosis of cancer before or at the baseline visit, then no antineoplastic treatment between the date of diagnosis and the baseline visit
Control Arm:
- At the baseline visit, >18 years old, any gender
- Not receiving treatment for or under surveillance for cancer at the baseline visit
- No indications of being monitored for or under consideration for suspected cancer at the baseline visit
- No diagnosis of cancer before or on the baseline visit or if any previous diagnosis of cancer, then cancer must have been curatively treated ≥ 5 years before the baseline visit
- No diagnosis of cancer within at least 365 days after the baseline visit
- At the baseline visit, available biospecimens for both EDTA-plasma and urine
Exploratory Arm:
- Same as Control Arm and type 2 diabetes or hypertension or BMI > 30 at the baseline visit
Exclusion Criteria
Case Arm:
- No available data for diagnosis of cancer starting 90 days before the baseline visit and up to 365 days after the baseline visit
- A subject with only a self-reported diagnosis of cancer (either in the 90 days before or in the 365 days after the baseline visit), and absence of a histopathological or clinically indicated diagnosis of cancer, according to biobank database(s), or through linkage with cancer registry(ies)
Control Arm and Exploratory Arm:
- No available data for diagnosis of cancer up to 365 days after or on the baseline visit
- A histopathological or clinically indicated diagnosis of cancer within 365 days from the baseline visit, according to biobank database(s), or through linkage with cancer registry(ies)
Sub-Study 2
Inclusion Criteria
- At the baseline visit, 35 - 80 years old, any gender
- Not receiving treatment for or under surveillance for cancer at the baseline visit
- No indications of being monitored for or under consideration for suspected cancer at the baseline visit
- No diagnosis of cancer before or on the baseline visit or if any previous diagnosis of cancer, then cancer must have been curatively treated ≥ 5 years before the baseline visit
- At the baseline visit, available biospecimens for both EDTA-plasma and urine
Exclusion Criteria
- No available data for diagnosis of cancer up to 365 days after the baseline visit
- A subject with only a self-reported diagnosis of cancer in the 365 days after the baseline visit and absence of a histopathological or clinically indicated diagnosis of cancer, according to biobank database(s), or through linkage with cancer registry(ies)
- Subjects not meeting the specifications for the target population eventually changed during test development in Sub-Study 1. Note that these specifications are pre-specified in the Statistical Analysis Plan and will be applied if they meet pre-specified acceptance criteria.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Sub-Study 1
Adults >= 18 years old with cancer or imminent cancer diagnosis (cases) versus cancer-free and no imminent cancer diagnosis (controls). Sub-Study 1 is intended for the development of 3 free GAGome MCED tests. |
The combined free GAGome MCED test aggregates measurements of plasma and urine GAGomes (the exhaustive human glycosaminoglycan profile) into a diagnostic score, the combined free GAGome MCED score.
The measurements are performed using MIRAM MCED Kits (Elypta AB) and the scores are computed using Elypta SKY Software (Elypta AB)
|
Sub-Study 2
Adults between 35 - 80 years old asymptomatic for cancer and with no recent history of cancer (> 5 years since curative-intent treatment for cancer). Sub-Study 2 is intended for the validation of the combined free GAGome MCED test (primary endpoint) and the plasma and urine free GAGome MCED tests (secondary endpoints). |
The combined free GAGome MCED test aggregates measurements of plasma and urine GAGomes (the exhaustive human glycosaminoglycan profile) into a diagnostic score, the combined free GAGome MCED score.
The measurements are performed using MIRAM MCED Kits (Elypta AB) and the scores are computed using Elypta SKY Software (Elypta AB)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and specificity of the combined free GAGome MCED test
Time Frame: Within 365 days after the baseline visit
|
Indicative of any-type cancer vs. no cancer diagnosis
|
Within 365 days after the baseline visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and specificity of the plasma free GAGome MCED test
Time Frame: Within 365 days after the baseline visit
|
Indicative of any-type cancer vs. no cancer diagnosis
|
Within 365 days after the baseline visit
|
Sensitivity and specificity of the urine free GAGome MCED test
Time Frame: Within 365 days after the baseline visit
|
Indicative of any-type cancer vs. no cancer diagnosis
|
Within 365 days after the baseline visit
|
Accuracy to the "putative cancer location" (PCL) model in the case (cancer) arm
Time Frame: Within 365 days after the baseline visit
|
Accuracy to the "putative cancer location" (PCL) model in the case (cancer) arm
|
Within 365 days after the baseline visit
|
Overall survival (OS) in the case (cancer) arm
Time Frame: From baseline visit until the date of death from any cause, assessed up to 15 years
|
Overall survival (OS) in the case (cancer) arm
|
From baseline visit until the date of death from any cause, assessed up to 15 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Francesco Gatto, PhD, Elypta AB
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- GR 21-063
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Combined free GAGome MCED test
-
PfizerCompleted
-
PfizerActive, not recruiting
-
University Hospital, Clermont-FerrandRecruitingAmyotrophic Lateral SclerosisFrance
-
Hacettepe UniversityCompletedGingival Recession | Shallow Vestibular DepthTurkey
-
Tanta UniversityRecruitingPostoperative Complications | Cardiac Surgery | Fluid OverloadEgypt
-
Odense University HospitalEnrolling by invitationNon-celiac Gluten Sensitivity; AdolescentsDenmark
-
PfizerCompleted
-
University of Illinois at Urbana-ChampaignIchuli Consulting LimitedUnknown
-
Woman's Health University Hospital, EgyptRecruiting
-
University College of Northern DenmarkRecruiting